Vitamin D in pregnant women from extreme areas of latitude: review from midwifery / Vitamina D en gestantes en zonas extremas: revisión desde la matronería

Insufficient vitamin D levels occur in 88.1% of the worlds population, which constitutes a global public health problem. We analyzed vitamin D deficiency and suggested vitamin D supplementation in the perinatal health of pregnant women living in geographical areas higher than 40° south-north latitude according to reviews from the last three decades and identifying midwives role. The methodology used was a qualitative systematic review of full text studies, conducted in geographical areas higher than 40°N and 40°S. Descriptors such as: "deficiency", "vitamin D", "pregnancy", "causes", "perinatal outcomes" and "supplementation", and their respective descriptors in Spanish. The matrices were tabulated according to the modified PRISMA. Eight studies were obtained in English from the Northern Hemisphere only, mostly with good quality evidence and related to the role of midwifing according to the expert round. The results showed risks such as: origin of the pregnant woman, ethnicity, low sun exposure, obesity, socioeconomic status, and perinatal risks. No studies were found in pregnant women from the Southern Hemisphere or related to the role of the midwife in this area. In conclusion, midwifery should considerer the social determinants of vitamin D deficiency in pregnant women, especially those in extreme southern areas where incorporation of supplementation are suggested as a public policy.

Los niveles insuficientes de vitamina D se dan en el 88,1% de la población mundial, lo que constituye un problema de salud pública global. Se analizó la deficiencia y la sugerencia de suplementación de vitamina D en la salud perinatal de las gestantes residentes en áreas geográficas de latitud 40° sur-norte según revisiones de las últimas tres décadas identificando el rol de la matrona. La metodología utilizada fue una revisión sistemática cualitativa de estudios a texto completo, realizados en áreas geográficas mayores al paralelo 40°N y 40°S. Descriptores como: "deficiencia", "vitamina D", "embarazo", "causas", "resultados perinatales" y "suplementación", y sus respectivos descriptores en español. Las matrices se tabularon según el PRISMA modificado. Se obtuvo ocho estudios en inglés pertenecientes sólo al hemisferio norte, la mayoría con buena calidad de evidencia. Los resultados arrojaron factores como origen de la embarazada, etnia, baja exposición al sol, obesidad, nivel socioeconómico y riesgos perinatales. No se encontraron estudios en mujeres embarazadas del hemisferio sur o relacionados con el papel de la matrona. En conclusión, desde el ejercicio de la matronería se deben considerar los determinantes sociales de las mujeres embarazadas especialmente de zonas extremas del sur donde se sugiere investigación experimental e incorporación de la suplementación como política pública.

Vitamin D supplementation during pregnancy to prevent vitamin D deficiency in newborns: a systematic review and meta-analysis / Suplementação de vitamina D durante a gravidez para a prevenção da deficiência de vitamina D em recém-nascidos: uma revisão sistemática e meta-análise

Abstract Objectives: to assess the effects of vitamin D supplementation during pregnancy on the outcomes of vitamin D concentration in newborns, length at birth, overall health (Apgar), birth weight and maternal vitamin D concentration after childbirth. Methods: this research was conducted in the electronic databases of MEDLINE, LILACS, EMBASE and Cochrane Library until December 2020, using the terms "vitamin D", "pregnancy", "vitamin D deficiency", "infant", "newborn" and their synonyms. Randomized controlled trials were searched by evaluating the effects of maternal vitamin D supplementation in neonates. The data was analyzed on RevMan 5.4 software and the quality of evidence on GRADE. Results: the newborn's overall health condition was presented as Apgar, with a mean difference (MD) of 0.15 (CI95%=0.06-0.25; p=0.002; I2=0%, two studies, 648 participants, moderate quality evidence) at the first minute and 0.11 (CI95%=0.04-0.17; p=0.001; I2=0%, two studies, 648 participants, moderate quality evidence) at the fifth minute. Significant effects were also presented at the length at birth considering any supplemented dose (MD=0.19; CI95%=0.08-0.30; p=0.0010; I2=0%, 1452 participants, low quality evidence) and birth weight in doses higher than 4000IU/day (MD=257.05 (CI95%=137.81-376.29; p<0.0001; I2=14%, 176 participants, moderate quality evidence). Conclusion: vitamin D supplementation during pregnancy improves serum 25 (OH) D concentration and suggests positive effects on overall health condition, length at birth and birth weight. PROSPERO CRD42017073292.

Resumo Objetivos: avaliar os efeitos da suplementação materna de vitamina D durante a gravidez nos desfechos concentração de vitamina D no recém-nascido, comprimento ao nascer, estado geral de saúde (Apgar), peso ao nascer e concentração de vitamina D materna após o nascimento. Métodos: a pesquisa foi conduzida nas bases de dados eletrônicas MEDLINE, LILACS, EMBASE e Cochrane Library até dezembro de 2020, utilizando os termos "vitamin D", "pregnancy", "vitamin D deficiency", "infant", "newborn" e seus sinônimos. Pesquisou-se por ensaios clínicos randomizados avaliando os efeitos da suplementação materna de vitamina D no neonato. Os dados foram analisados pelo software RevMan 5.4 e a avaliação da qualidade das evidências pelo GRADE. Resultados: o estado geral de saúde do recém-nascido foi apresentado como Apgar, com uma diferença de média (DM) de 0,15 (IC95%=0,06-0,25; p=0,002; I2=0%, dois estudos, 648 participantes, evidência de qualidade moderada) para o teste no primeiro minuto e 0,11 (IC95%=0,04-0,17; p=0,001; I2=0%, dois estudos, 648 participantes, evidência de qualidade moderada) para quinto minuto. Efeitos significativos também foram apresentados para o comprimento ao nascer em qualquer dose suplementada (DM=0,19 (IC95%=0,08-0,30; p=0,0010; I2=0%, 1452 participantes, evidência de baixa qualidade) e peso ao nascer em doses maiores que 4000UI/dia (DM=257,05 (IC95%=137,81-376,29; p<0,0001; I2=14%, 176 participantes, evidência de qualidade moderada). Conclusão: a suplementação de vitamina D durante a gravidez melhora a concentração sérica de 25 (OH)D e sugere apresentar efeitos positivos no estado geral de saúde, comprimento ao nascer e peso ao nascer. PROSPERO CRD42017073292.

Association between vitamin D and cardioprotection in adult patients

SUMMARY OBJECTIVE: To conduct a review of articles which have evaluated the relationship between vitamin D and cardioprotection in adult. METHODS: A literature search was performed in the Pubmed and Scielo databases. The results were extracted from primary and secondary sources and will be presented in the form of a bibliographic review. RESULTS: Twenty-three articles were identified from the electronic search that reported on physiological mechanisms relating the vitamin D axis and the cardiovascular system through receptors. Of the ten studies that evaluated the therapeutic effect of vitamin D in cardiovascular diseases, none reported significant results. CONCLUSION: The articles assessed in this review did not demonstrate a cardioprotective effect of vitamin D, despite the epidemiological correlation of vitamin D deficiency with a higher prevalence of cardiovascular diseases.

Efecto de la suplementación con vitamina D en dosis única sobre el estado nutricional de vitamina D / Effect of vitamin D supplementation as a single dose on the nutritional status of vitamin D

INTRODUCCIÓN: El primer año de vida es un periodo de riesgo de deficiencia de vitamina D (VD). La administración de 400 UI diarias de VD no tiene una adherencia del 100%, en cambio dosis únicas de 100.000 UI de VD oral son seguras en recién nacidos. OBJETIVO: Comparar el efecto de la suplementación oral de VD en dosis única de 100.000 UI al mes de edad vs dosis diarias de 400 UI sobre las concentraciones séricas de VD, a los 6 meses de vida. SUJETOS Y MÉTODOS: Ensayo clínico aleatorizado, sin enmascaramiento. Se incluyeron 84 lactantes sanos de 1 mes de vida, asignados al azar al grupo de estudio (GE) que recibió una dosis única de VD de 100.000 UI oral o al grupo control (GC), que recibió dosis diarias de VD de 400 UI oral del 1er al 6to mes de vida. A los 6 meses de edad se determinó la concentración sérica de VD. RESULTADOS: 65 lactantes terminaron el estudio, 36 en GE y 29 en GC. No se encontró deficiencia de VD. La insuficiencia de VD fue de 5,5% y 6,8% en el GE y GC, respectivamente. La concentración sérica de VD a los 6 meses de vida, fue de 38,8 ± 5,2 ng/ml y 39,7 ± 6,3 ng/ml para GE y GC, respectivamente (NS). CONCLUSIONES: La suplementación con 100.000 UI de VD única al mes de edad logra concentraciones séricas de VD a los 6 meses de vida, similares a dosis diarias de 400 UI de VD, del 1er al 6to mes.

INTRODUCTION: Infants are a group at risk of vitamin D (VD) deficiency. The administration of 400 IU of VD per day during the first year of life does not achieve 100% adherence. A single dose of 100,000 IU of oral VD is safe in newborns. OBJECTIVE: To compare the effect of oral administration of VD between a single dose of 100,000 IU at one month of age vs daily doses of 400 IU on serum concentrations of VD, at 6 months of age. SUBJECTS AND METHOD: Randomized clinical trial, without masking. 84 healthy infants were included at 1 month of age, randomized to the study group (SG) receiving a single oral dose of 100,000 IU or to the control group (CG), who received daily oral doses of VD of 400 IU from the 1st to the 6th month of life. At 6 months of life, the serum concentration of VD was determined. RESULTS: 65 infants completed the study, 36 in SG and 29 in CG. No VD deficiency was found. VD insufficient was 5.5% and 6.8% in the SG and CG, respectively. The serum concentration of VD at six months of age was 38.8 ± 5.2 ng/ml and 39.7 ± 6.3 ng/ml for the SG and CG, respectively (NS). CONCLUSIONS: Supplementation of 100,000 IU of VD at one month age achieves serum concentrations of VD at 6 months of life similar to the administration of daily doses of 400 IU of VD from the 1st to the 6th month.

Osteomalacia. Diagnóstico y tratamiento / Osteomalacia. Diagnosis and treatment

Introducción: la osteomalacia se caracteriza por la falta de mineralización de la sustancia osteoide, que afecta al hueso cortical y al hueso esponjoso maduro. Es una enfermedad que se presenta en adultos y niños, aunque la causa es diferente en cada uno. Objetivo: exponer la generalidad de la osteomalacia por ser una enfermedad que produce serias afectaciones a la población que la padece, especialmente a los niños. Se enfatiza en el diagnóstico y su tratamiento. Desarrollo: a fin de resumir los elementos esenciales para establecer el diagnóstico de osteomalacia hay que plantear en primer lugar, la presencia de un trastorno de la mineralización ósea, de ahí que además de tener en cuenta las causas de la enfermedad, su curso clínico y la sintomatología. Conclusiones: una recomendación importante es no tener en cuenta la posibilidad de complicaciones en el curso de la enfermedad, como las fracturas, que, aunque sean parte del cuadro clínico, al producirse pueden ocasionar graves problemas, como el caso de las que aparecen en las costillas, que si se desplazan pueden interesar órganos vitales, de modo que en este tipo de pacientes no debe excluirse la posibilidad de emergencias o de urgencias reumatológicas tanto en los adultos como en los niños(AU)

Introduction: osteomalacia is characterized by the lack of mineralization of the osteoid substance, which affects cortical bone and mature cancellous bone. It is a disease that occurs in adults and children, although the cause is different in each. Objective: to expose the generality of osteomalacia for being a disease that causes serious affectations to the population that suffers it, especially to children. Emphasis is placed on the diagnosis and its treatment. Development: in order to summarize the essential elements to establish the diagnosis of osteomalacia, we must first consider the presence of a bone mineralization disorder, hence, in addition to taking into account the causes of the disease, its clinical course and the symptomatology. Conclusions: an important recommendation is not to take into account the possibility of complications in the course of the disease, such as fractures, which, although they are part of the clinical picture, can cause serious problems when they occur, as in the case of those that appear in the ribs, which if they move may involve vital organs, so that in this type of patients should not exclude the possibility of emergencies or rheumatological emergencies in both adults and children(AU)

Influencia de la estación del año en los niveles de vitamina D de una población pediátrica / Influence of the season of the year in vitamin D levels in a pediatric population

Introducción: El objetivo de nuestro trabajo es determinar los niveles séricos de 25 (OH) vitamina D en una población pediátrica de la Ciudad de Rosario y sus alrededores y la influencia de las diferentes estaciones del año sobrelos mismos.Material y métodos: Estudio prospectivo observacional en el que se dosó el nivel de vitamina D en niños de ambossexos menores de 15 años de edad. El plazo de medición fue de un año calendario para posteriormente y analizarsus niveles según las cuatro estaciones del año. Todos los análisis de vitamina D fueron realizados por el mismolaboratorio y el mismo equipo de medición.Resultados: Se incluyeron 128 pacientes de ambos sexos. Del total de mediciones se encontraron niveles inferioresa 30 ng/ml en el 61,7% (n=79). Las medias de los niveles de Vitamina D fueron en otoño 32,6 ng/ml (±12,3);invierno 24,4 ng/ml (±8,7); primavera 24,1 ng/ml (±7,2) y en verano 27,8 ng/ml (±10,8). Existieron diferenciassignificativas entre las estaciones de otoño y primavera (p< 0,001) y entre otoño e invierno (p<0,004). Otoño fue laúnica estación que presentó niveles superiores a 30 ng/ml (media: 32,6).Conclusiones: Existe una alta prevalencia de niveles bajos de vitamina D (según lo publicado en la literatura a nivelinternacional). Recomendamos su dosaje especialmente en las estaciones de invierno, primavera y verano (AU)

Introduction: The purpose of our work is to determine the serum levels of 25 (OH) vitamin D in a pediatric populationof the City of Rosario and surrounding areas, and the influence of the different seasons of the year on them.Material and methods: A prospective observational study in which the level of vitamin D was measured in children ofboth sexes under 15 years of age. The measurement period was one calendar year to be subsequently analyzed accordingto the four seasons of the year. All vitamin D tests were performed by the same laboratory and the same measurementequipment. Results: 128 patients of both sexes were included. Of the total measurements, levels lower than 30 ng / ml were found in61.7% (n = 79). The averages of Vitamin D levels were: in autumn 32.6 ng / ml (±12,3); winter 24.4 ng / ml (±8,7);spring 24.1 ng / ml (±7,2) and summer 27.8 ng / ml (±10,8). There were significant differences between the autumn andspring seasons (p <0.001) and between autumn and winter (p <0.004). Autumn was the only station that presented levelshigher than 30 ng / ml (mean: 32.6).Conclusions: There is a high prevalence of low levels of vitamin D (as published in the international literature). We recommend its dosing especially in the winter, spring and summer seasons (AU)

Vitamin B12, bone mineral density and fracture risk in adults: A systematic review / Vitamina B12, densidade mineral óssea e risco de fraturas em adultos: uma revisão sistemática

Summary Objective: To consolidate information available on the effect of vitamin B12 on bone mineral density and fracture risk, with emphasis on clinical trials, observational and longitudinal data conducted in humans. Method: A systematic review of the literature of the past decade on the role of vitamin B12 in bone mineral density and fracture risk in subjects of all ages and both sexes was performed by means of a PubMed, Science Direct, Medline and SciELO database search. Articles included in this review were identified using the search terms: B12 Vitamin and Bone Mineral Density and Vitamin B12 and Risk of Fractures. Evidence quality of the included articles was evaluated by GRADE system. Results: A total of 25 original studies were identified. After reviewing the titles and abstracts of articles, only 17 articles met the inclusion criteria. The present review provides evidence that the role of vitamin B12 on bone mineral density or fracture risk should be further elucidated. Controversies are explained by heterogeneity of methodologies used for the diagnosis of vitamin B12 and also by differences among populations investigated on the studies. Conclusion: A real effect of vitamin B12 deficiency in bone health and the mechanisms associated with bone metabolism is not well established yet. It is extremely important to carry out more clarifying studies about this theme, especially with vulnerable groups such as postmenopausal and elderly women, as is well-known that they are greatly affected by deficiency of this vitamin.

Resumo Objetivo: Consolidar as informações disponíveis acerca dos efeitos da vitamina B12 sobre a densidade mineral óssea e o risco de fraturas, com destaque para ensaios clínicos, dados observacionais e longitudinais realizados com humanos. Método: Foi realizada uma revisão sistemática da literatura dos últimos dez anos sobre o papel da vitamina B12 na densidade mineral óssea e no risco de fraturas em populações de todas as idades e para ambos os sexos, com busca de artigos nos bancos de dados eletrônicos: PubMed, Science Direct, Medline e SciELO. Como estratégia de busca de dados incluíram-se os descritores: B12 Vitamin and Bone Mineral Density e B12 Vitamin and Risk of Fractures. A qualidade das evidências dos artigos incluídos foi avaliada pelo sistema GRADE. Resultados: Após a análise dos títulos e dos resumos dos artigos, a estratégia de busca resultou em 25 referências, das quais 17 artigos preencheram os critérios de elegibilidade. Esta revisão fornece evidências de que o papel da vitamina B12 sobre a densidade mineral óssea ou o risco de fraturas ainda precisa ser mais bem elucidado. As controvérsias encontram respaldo na heterogeneidade das metodologias utilizadas para o diagnóstico da vitamina B12 e também na variedade de populações presentes entre os estudos. Conclusão: Ainda não está bem estabelecido o real impacto da deficiência de vitamina B12 na saúde dos ossos e sobre os mecanismos associados ao metabolismo ósseo. É de suma importância a realização de mais estudos esclarecedores, principalmente em grupos vulneráveis como as mulheres pós-menopausa e os idosos, grupos estes bastante afetados pela deficiência dessa vitamina.

Preterm Preeclampsia and Timing of Delivery: A Systematic Literature Review / Pré-eclâmpsia pré-termo e o melhor momento para a resolução da gestação: revisão sistemática da literatura

Abstract Introduction Preeclampsia, a multifactorial disease with pathophysiology not yet fully understood, is a major cause of maternal and perinatal morbidity and mortality, especially when preterm. The diagnosis is performed when there is an association between arterial hypertension and proteinuria or evidence of severity. There are unanswered questions in the literature considering the timing of delivery once preterm preeclampsia has been diagnosed, given the risk of developingmaternal complications versus the risk of adverse perinatal outcomes associated with prematurity. The objective of this systematic review is to determine the best timing of delivery for women diagnosed with preeclampsia before 37 weeks of gestation. Methods Systematic literature review, performed in the PubMed database, using the terms preeclampsia, parturition and timing of delivery to look for studies conducted between 2014 and 2017. Studies that compared the maternal and perinatal outcomes of women who underwent immediate delivery or delayed delivery, in the absence of evidence of severe preeclampsia, were selected. Results A total of 629 studies were initially retrieved. After reading the titles, 78 were selected, and their abstracts, evaluated; 16 were then evaluated in full and, in the end, 6 studies (2 randomized clinical trials and 4 observational studies) met the inclusion criteria. The results were presented according to gestational age range (< 34 weeks and between 34 and 37 weeks) and by maternal and perinatal outcomes, according to the timing of delivery, considering immediate delivery or expectant management. Before 34 weeks, thematernal outcomeswere similar, but the perinatal outcomes were significantly worse when immediate delivery occurred. Between 34 and 37 weeks, the progression to severe maternal disease was slightly higher among women undergoing expectant management, however, with better perinatal outcomes. Conclusions When there is no evidence of severe preeclampsia or impaired fetal wellbeing, especially before 34 weeks, the pregnancy should be carefully surveilled, and the delivery, postponed, aiming at improving the perinatal outcomes. Between 34 and 37 weeks, the decision on the timing of delivery should be shared with the pregnant woman and her family, after providing information regarding the risks of adverse outcomes associated with preeclampsia and prematurity.

Resumo Introdução A pré-eclâmpsia, doença multifatorial e com fisiopatologia ainda não totalmente estabelecida, é importante causa de morbimortalidade materna e perinatal, especialmente quando pré-termo. O diagnóstico é realizado quando há associação entre hipertensão arterial e proteinúria ou evidência de gravidade. Existem questionamentos na literatura se, frente ao diagnóstico de pré-eclâmpsia, a resolução da gravidez deve ser imediata ou postergada, considerando o risco de desenvolvimento de complicações maternas versus os resultados perinatais associados à prematuridade. O objetivo desta revisão sistemática é estabelecer o melhor momento de resolução da gestação em mulheres com pré-eclâmpsia antes das 37 semanas. Metodologia Revisão sistemática da literatura, realizada na base de dados PubMed, usando os termos preeclampsia parturition e timing of delivery, para encontrar estudos feitos entre 2014 a 2017. Foram selecionados estudos que comparassem os desfechos maternos e perinatais de mulheres submetidas a resolução imediata ou a postergação do parto, na ausência de evidência de pré-eclâmpsia grave. Resultados Foram localizados 629 artigos; após leitura dos títulos, 78 foram selecionados. Realizada avaliação dos seus resumos, 16 foram avaliados na integralmente e, finalmente, 6 estudos preencheram os requisitos de inclusão (2 ensaios clínicos randomizados e 4 estudos observacionais). Os resultados foram apresentados conforme a faixa de idade gestacional (± 34 semanas, e entre 34 e 37 semanas) e a avaliação dos desfechos maternos e perinatais. Antes das 34 semanas, os resultados maternos foram semelhantes; entretanto, os desfechos perinatais foram significativamente piores quando houve resolução imediata. Entre 34 e 37 semanas, a progressão para doença materna grave foi discretamente maior entre as mulheres submetidas a conduta expectante; entretanto, os desfechos perinatais forammelhores quando o parto foi postergado. Conclusões Na ausência de evidências de pré-eclâmpsia grave ou de prejuízo da vitalidade fetal, o parto deve ser postergado, principalmente antes das 34 semanas, com vigilância materna e fetal rigorosas. Entre 34 e 37 semanas, a decisão deve ser compartilhada com a gestante e sua família, após esclarecimento sobre os desfechos adversos associados à pré-eclâmpsia e prematuridade.

What do Cochrane systematic reviews say about interventions for vitamin D supplementation?

ABSTRACT CONTEXT AND OBJECTIVE: Despite the high prevalence of vitamin D supplementation, its use remains controversial. The objective of this review was to identify and summarize the evidence from Cochrane systematic reviews regarding vitamin D supplementation for preventing ortreating any clinical condition. DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo. METHODS: A search was conducted to identify all Cochrane systematic reviews that fulfilled the inclusion criteria. Titles and abstracts were screened by two authors. RESULTS: We included 27 Cochrane systematic reviews: 10 assessing use of vitamin D for prevention and 17 for treatment. The reviews found moderate to high quality of evidence regarding the benefit of vitamin D for pregnant women (prevention of adverse events: preterm birth risk [rate ratio, RR 0.36; 95% confidence interval, CI 0.14 to 0.93] and low birthweight risk [RR 0.40; 95% CI 0.24 to 0.67]) and for asthma patients (reduction of severe exacerbations [RR 0.63; 95% CI 0.45 to 0.88]). No benefit was found regarding vitamin D supplementation alone (without calcium) for preventing hip or any new fracture. For all other outcomes assessed under various conditions, the current quality of evidence is low or unknown, and therefore insufficient for any recommendation. CONCLUSION: Based on moderate to high quality of evidence, the Cochrane systematic reviews included here showed that there were some benefits from vitamin D supplementation for pregnant women and asthma patients and no benefits for preventing fractures.

Déficit de vitamina D. Revisión epidemiológica actual / Vitamin D deficiency. Current epidemiological review

Vitamin D is a liposoluble hormone that exists in two molecular forms. Ergocalciferol (vitamin D-2) and colecalciferol (vitamin D-3). Vitamin D-3 is produced in the skin by the action of UV-B radiation. Both forms are metabolized by the liver to 25-hydroxy-Vit D (25OHD) and later in the kidney to the active form 1,25-dihydroxy-Vit D. This form promotes bone mineralization by intestinal absorption of calcium and phosphate. Normal levels of 25OHD are associated with less fracture, normal neuromuscular and immune function and possibly have a preventive effect on certain types of cancer. The Endocrine Society's Clinical Practice Guidelines recommends that optimal plasma levels of 25OHD are above 30 ng/ml, insufficiency between 21 and 29 ng/ml and deficiency below 20 ng/ml. The prevalence rate of 25OHD deficit is about 2 to 90% in different populations. Risk factors of Vitamin D deficit like year season, skin pigmentation, sunlight exposition, use of sunblock and inadecuate Vitamin D ingestion, together with different measurement techniques explain the variability of results between epidemiological studies. An important risk group is the health professionals that are not exposed to sunlight. There are no studies that describe the prevalence in this population in Chile. (AU)

Vitamina D en niños con enfermedades neurológicas en la edad pediátrica / The role of vitamin D in neurological diseases in children

La vitamina D (VD) y sus acciones en el ser humano son objeto de una activa investigación en años recientes, ligada a la descripción de nuevos roles metabólicos, además de su conocida participación en el metabolismo del calcio y del hueso. En niños, algunas enfermedades neurológicas crónicas, como la parálisis cerebral, presentan un riesgo aumentado de deficiencia de VD, explicándose por una ingesta deficiente de ella, una menor exposición solar, requerimiento asociado al proceso de crecimiento, enfermedades intercurrentes y al uso frecuente de drogas antiepilépticas. En esta revisión se analizan los factores asociados a la deficiencia de VD y se plantea la necesidad de evaluar sistemáticamente el estado nutricional de esta vitamina en pacientes con enfermedades neurológicas de riesgo, sus posibles efectos metabólicos, implicancias clínicas y la necesidad de usar alimentos fortificados o suplementación con VD.

Vitamin D (VD) has been object of an active research in the last years, especially in relation with the findings of its new roles, besides its well known participation in calcium and bone metabolism. In children, some chronic neurologic diseases, like cerebral palsy, show an increased risk of VD deficiency, which could be explained by low intake, reduced sun exposure, requirements associated to growth process, intercurrent diseases and frequent use of antiepileptic drugs. In this review, factors associated to VD deficiency are analyzed, pointing to the need of a systematic assessment of the VD nutritional status in patients with neurological diseases associated to this deficiency, its possible metabolic effects, clinical implications and the need of fortified foods or VD supplementation.

Algunas estrategias de prevención para mantener la autonomía y funcionalidad del adulto mayor / Autonomy and functional status in the elderly: some prevention strategies

La meta de la geriatría es mantener la autonomía y funcionalidad de los adultos mayores a pesar del cúmulo de daño adquirido con anterioridad. En este artículo, se enfatiza la necesidad de un programa de vacunación que incluya las vacunas antineumococica, anti herpes zoster, tétano y difteria. La pesquisa del cáncer cérvico uterino, de mama y colo rectal. Un IMC entre 25 kg/m2 y 30 kg/m2 en mayores de 75 años produce la menor mortalidad cardio vascular y general. Los factores más importantes en la ocurrencia de caídas son: disminución de la fuerza muscular, dificultad en la marcha y uso de medicamentos. Se enfatiza la necesidad de evaluar la conducción segura de automóviles. Analizamos, los efectos deletéreos del déficit de vitamina D, presente en la mayoría de los adultos mayores, en el riesgo de caer, sistema inmune, mortalidad general y enfermedades neurodegenerativas

The goal of geriatric medicine is to maintain autonomy and functionality in elderly people, in spite of damage accumulated earlier in life. In this review we emphasize the importance of vaccination programs for elderly people, including vaccines such as anti pneumococcal, anti herpes zoster, tetanus y diphtheria and also, the need of programs of early diagnosis of cervical cancer, breast cancer and colorectal cancer. Research shows that a Body Mass Index between >25 kg/m2 and 30 kg/m2 in persons over 75 years of age, reduces cardiovascular deaths and deaths in general. Research also demonstrates that diminishing of muscular strength, difficulty to walk, plus the use of medications are the most important factors to be taken into account in preventing falls. It is very important to periodically evaluate safe car driving. Vitamin D deficit increases incidence of falls, immune system alterations, neurodegenerative illness and mortality

Evidence-based non-skeletal actions of vitamin D / Evidências das ações não esqueléticas da vitamina D

Vitamin D is a major regulator of mineral homeostasis through its action in the kidney, intestine, bone and parathyroid glands. On these tissues, its active form, calcitriol, acts by binding to a specific nuclear receptor that belongs to the steroid/thyroid hormone receptor family. This receptor, however, has also been identified in several additional human tissues. So, apart from its traditional actions related to calcium, vitamin D and its synthetic analogs are being increasingly recognized for their anti-proliferative, pro-differentiative and immunomodulatory activities. Low levels of vitamin D have been linked to many chronic diseases. Decreased muscle function and increased fall risk in elderly people; prostate, breast and colorectal cancers; diabetes mellitus; and other health problems have been associated to low circulating levels of 25-hydroxyvitamin D. This paper presents an overview of the available scientific evidence for the non-calcemic actions of vitamin D in humans.

A vitamina D é um importante regulador da homeostase mineral por meio de sua ação nos rins, no intestino, nos ossos e nas glândulas paratireoides. Nesses tecidos, sua forma ativa, o calcitriol, atua ligando-se a um receptor nuclear específico, pertencente à família de receptores dos hormônios esteroides e tireoidianos. Contudo, esse receptor também foi identificado em outros tecidos humanos. Assim, além de suas ações tradicionais, relacionadas ao metabolismo do cálcio, a vitamina D e análogos sintéticos estão, cada vez mais, sendo reconhecidos por seus efeitos antiproliferativos, pró-diferenciação e imunomodulatórios. Baixas concentrações séricas de vitamina D têm sido associadas a várias doenças crônicas. Redução da função muscular e aumento do risco de quedas em idosos; câncer de próstata, mama e colorretal; diabetes melito; e outros problemas de saúde têm sido associados a concentrações circulantes baixas de 25-hidroxivitamina D. Este trabalho apresenta uma visão geral sobre as evidências científicas disponíveis das ações não calcêmicas da vitamina D em humanos.

Bioavailability of vitamin D3 in non-oily capsules: the role of formulated compounds and implications for intermittent replacement / Biodisponibilidade da vitamina D3 em cápsulas não oleosas: o papel das formulações manipuladas e as implicações para a substituição intermitente

OBJECTIVE: To evaluate the bioavailability of vitamin D in capsules as compared with oily drops in nuns living in a closed community with very low sun exposure. METHODS: A randomized, 2 x 2 crossover, open clinical trial was conducted, with 18 nuns aged between 20 and 75 years. Samples were collected in the fasting state and at 4, 8, 12 and 24 hours following the administration of capsules and oily drops (both containing vitamin D3 66,000 UI plus vitamin A 13,200 UI) to determine serum 25 hydroxivitamin D concentrations (25OHD), at baseline and 90 days after. The evaluation was based on the maximum concentration (Cmax) and area under the curve (AUC0-24). RESULTS: The capsule formulation presented Cmax and AUC0-24, 5.78 percent and 0.76 percent, respectively, greater than the oily drops formulation. CONCLUSION: Both formulations were within the limits for a bioequivalence study, namely C-90 percent for Cmax and AUC0-24, and the drugs were considered bioequivalent.

OBJETIVO: Avaliar a biodisponibilidade da vitamina D3 em cápsulas, comparando com gotas oleosas, em religiosas que vivem em comunidade fechada com baixa exposição solar. MÉTODOS: Ensaio clínico aberto, aleatório e cruzado 2 x 2, com 18 religiosas (20-75 anos de idade). As amostras foram coletadas em jejum e 4, 8, 12 e 24 horas após a administração de cápsulas e de gotas oleosas (ambos contendo 66.000 UI de vitamina D3 e 13.200 UI de vitamina A) para dosagem da 25 hidroxivitamina D (25OHD), em data base e 90 dias após. A avaliação baseou-se nos resultados da concentração máxima (Cmáx) da 25OHD e da área sob a curva (ASC0-24). RESULTADOS: A análise descritiva desses parâmetros demonstrou que a cápsula apresentou Cmáx e ASC0-24 de 5,78 por cento e 0,76 por cento a mais que as gotas oleosas, respectivamente. CONCLUSÃO: Ambas as formulações encontravam-se dentro dos limites de aceitação em estudo de bioequivalência IC-90 por cento para Cmáx e ASC (0-24), daí as drogas serem consideradas bioequivalentes.